Acadia Pharmaceuticals stock price target lowered to $33 by H.C. Wainwright
H.C. Wainwright lowered its price target on Acadia Pharmaceuticals (ACAD) to $33 from $37, citing a Phase 2 trial miss. The stock fell 22% to $20.68. Despite this, some analysts see value, with price targets up to $49. The trial missed its primary endpoint but hit a key secondary endpoint.
How this was made
The 30-second read
Why it matters
The mixed results prompted multiple analysts to lower price targets, indicating heightened risk perception.
Market read
The trial outcome and subsequent target cuts create short‑term downside risk for ACAD and may influence sentiment in the neuro‑psychiatric biotech niche.
What to watch
Potential for Phase 3 amendments could mitigate the impact of the Phase 2 miss.
Background
Acadia Pharmaceuticals reported Phase 2 data for remlifanserin in Alzheimer’s disease psychosis, missing the primary endpoint but hitting a key secondary endpoint.
Ticker impact
H.C. Wainwright lowered ACAD's price target to $33 after the Phase 2 trial narrowly missed its primary endpoint.
likely pressure as investors price in the reduced target and trial uncertainty
Analyst target reduction and 22% price drop reflect market reaction to the trial miss.
Market effects
Biotech sector may see broader caution on Alzheimer’s‑related trials.
U.S. biotech stocks could face short‑term pressure.
Limited to investors tracking clinical‑trial outcomes.
Counterpoint
Some investors may view the secondary endpoint success as a catalyst for upside.
Key entities
- companyAcadia Pharmaceuticals
Biopharma developing remlifanserin.
- analyst_firmH.C. Wainwright
Reduced ACAD price target to $33.
